Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +47.86%
#3 Velvet Velvet +43.20%
#4 Akedo Akedo +42.96%
#5 Black Phoenix Black Phoenix +34.22%
#6 Cross Cross +21.95%
#7 DoubleZero DoubleZero +17.10%
#8 Cap Cap +16.75%
#9 Tutorial Tutorial +15.51%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.76%
Coin of the day
Islamic Coin Islamic Coin
설정
언어
한국어
통화
USD
테마
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
주식 순위 #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
주가
$0.11725176
마지막 동기화: 2025-07-14
시가총액
$481.50K
변동 (1일)
-0.20%
변동 (1년)
0.00%
국가
FR
거래 PHAXIAM Therapeutics S.A. (PHXM)

카테고리

Healthcare
PHAXIAM Therapeutics S.A. (PHXM)의 수익
Jun 2024 기준 수익 TTM: $-23.51M
PHAXIAM Therapeutics S.A.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-23.51M입니다. 2022년에 회사는 $-1.28M의 수익을 올렸으며 이는 2021년의 수익 $-65.34M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
PHAXIAM Therapeutics S.A.의 수익 기록 (2016 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-23.51M -14.00%
2023 $-27.34M 2,036.64%
2022 $-1.28M -98.04%
2021 $-65.34M -30.07%
2020 $-93.44M 25.10%
2019 $-74.70M 52.60%
2018 $-48.95M 11.10%
2017 $-44.06M 64.85%
2016 $-26.73M 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -22,533.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -8,395.72%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -12,882.70%
BE